Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications DOI Creative Commons

Roxana-Cristina Dobriceanu,

Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 891 - 891

Опубликована: Апрель 7, 2025

Diabetes mellitus (DM) is a multifactorial metabolic disorder associated with systemic inflammation and vascular complications. Pentraxin-3 (PTX3) has emerged as key biomarker of endothelial dysfunction in DM. We aimed to examine the role PTX3 DM assesses impact pharmacological interventions on its expression. The review included studies analyzing modulation by antidiabetic therapies, such sodium-glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 agonists (GLP-1a), dipeptidyl peptidase-4 (DPP-4i), well effects lifestyle interventions. Clinical experimental demonstrated strong correlation between levels progression. Elevated were diabetic complications, including nephropathy, retinopathy, cardiovascular diseases. Antidiabetic drugs showed differential expression, GLP-1a DPP-4i significantly reducing levels, while SGLT-2i displayed paradoxical increase. Lifestyle interventions, dietary modifications weight loss, yielded inconsistent effects, suggesting genetic factors influence regulation. While particularly DPP-4i, demonstrate anti-inflammatory further research needed standardize measurement explore potential therapeutic target. Personalized treatment strategies incorporating profiling may optimize control disease management patients.

Язык: Английский

APOE Drives Glioma Progression by Modulating CCL5/CCR5 Signaling in the Tumor Microenvironment and Inducing M2 Macrophage Polarization DOI Creative Commons
Wei Huang, Weimin Li, Xingyu Chen

и другие.

Immunobiology, Год журнала: 2025, Номер 230(3), С. 152895 - 152895

Опубликована: Март 22, 2025

Tumor-associated macrophages (TAMs) are pivotal in shaping the tumor microenvironment (TME) during cancer progression. Emerging evidence indicates that dysregulation of key signaling pathways cells drives secretion various cytokines, modulating TAMs function. This study aimed to explore how glioblastoma regulate and establish a TME conducive immune escape. In previous bioinformatics studies, we identified abnormally expressed genes patients. Among them, metabolism-related protein APOE garnered particular attention. We generated U87 U251 cell lines with altered expression evaluate invasion, migration, inflammatory cytokine through scratch assays, Transwell ELISA, respectively. Additionally, established co-culture system monocytes THP-1 assess impact shAPOE on macrophage polarization using flow cytometry, Western blot, immunofluorescence techniques. Knockdown significantly reduced viability, migration capabilities cells. ELISA results also showed knockdown secreted higher levels IL-6, IL-12, TNF-α, while CCL5 TGF-β was markedly reduced. observed M1/M2 ratio monocytes, CCR5 inhibition further decreasing M2 proportions. Immunofluorescence analysis revealed reduction dependent CCL5. Our findings indicate suppresses secretion, enhancing production tumor-suppressive cytokines.

Язык: Английский

Процитировано

0
Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications DOI Creative Commons

Roxana-Cristina Dobriceanu,

Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc

и другие.

Biomedicines, Год журнала: 2025, Номер 13(4), С. 891 - 891

Опубликована: Апрель 7, 2025

Diabetes mellitus (DM) is a multifactorial metabolic disorder associated with systemic inflammation and vascular complications. Pentraxin-3 (PTX3) has emerged as key biomarker of endothelial dysfunction in DM. We aimed to examine the role PTX3 DM assesses impact pharmacological interventions on its expression. The review included studies analyzing modulation by antidiabetic therapies, such sodium-glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 agonists (GLP-1a), dipeptidyl peptidase-4 (DPP-4i), well effects lifestyle interventions. Clinical experimental demonstrated strong correlation between levels progression. Elevated were diabetic complications, including nephropathy, retinopathy, cardiovascular diseases. Antidiabetic drugs showed differential expression, GLP-1a DPP-4i significantly reducing levels, while SGLT-2i displayed paradoxical increase. Lifestyle interventions, dietary modifications weight loss, yielded inconsistent effects, suggesting genetic factors influence regulation. While particularly DPP-4i, demonstrate anti-inflammatory further research needed standardize measurement explore potential therapeutic target. Personalized treatment strategies incorporating profiling may optimize control disease management patients.

Язык: Английский

Процитировано

0